Mobia Medical: First Public Quarter Blowout Growth and a $30B Stroke Recovery Opportunity
IPO fuels expansion of Vivistim therapy as revenue nearly doubles, but can the company sustain its measured territory growth?
MOBI · Earnings Call · 2026-08-11
A New Public Name with a Clear Thesis
Mobia Medical (MOBI) reported its first earnings call as a public company on August 11, delivering a quarter that validated the IPO thesis. Revenue came in at $13.5 million, up 102% year-over-year, and the company initiated full-year 2026 guidance of $54–56 million, implying 69–75% growth. The company's Vivistim therapy — an FDA-approved paired vagus nerve stimulation system for chronic stroke survivors — is at the center of this growth. As CEO Richard Foust put it, “We delivered a strong second quarter with financial performance reflecting continued commercial adoption of our Vivistim Paired VNS therapy for upper extremity impairment in chronic ischemic stroke survivors.” — Richard Foust, President and Chief Executive Officer · 2026-08-11 The company's commercial model relies on a "stable, predictable" expansion of active territories. In Q2, average active territories grew 92% to 35.5, and the company sold approximately 367 units. CFO Nelson Curnes noted, “Our patient funnel continues to create consistent, predictable revenues for our business.” — Nelson Curnes, Chief Financial Officer · 2026-08-11 This is a classic execution story, but the key question is whether the growth can continue at this pace.Reimbursement Momentum and a Massive TAM
A critical catalyst for Vivistim is reimbursement. The company has a Category 1 CPT code and, in 2026, CMS assigned it to New Tech APC 1580 under the hospital outpatient prospective payment system, with Medicare reimbursement of approximately $45,000. Richard Foust highlighted that this is a proposal for 2027, but “that gives us a lot of stability and predictability associated with payment.” — Richard Foust, President and Chief Executive Officer · 2026-08-11 This reimbursement clarity is foundational for the $30 billion serviceable market the company estimates in the U.S. alone. The company is targeting stroke centers—about 1,500 primary and comprehensive centers—which are concentrated and specialized. The stroke survivor population is vast, with 9 million ischemic stroke survivors in the U.S., and Vivistim works regardless of time since stroke, even treating patients up to 45 years post-stroke. This opens up the existing prevalence population, not just new incident cases.Territory Rollout: Measured but Ambitious
The company's guidance implies a deceleration from the 102% growth in Q2 to around 70% for the full year. This reflects a "measured approach" to adding territories. When asked about the back half, Bunker Curnes said, “the approximate range, kind of the 4 or 5 for the back half of the year would be a comfortable number for us.” — Nelson Curnes, Chief Financial Officer · 2026-08-11 This suggests the company is being disciplined about capital deployment, even with IPO proceeds of $134 million on the balance sheet. The IPO has also helped with talent acquisition. Foust noted, “the IPO has just given us a bigger platform to talk about all the great things that we're doing.” — Richard Foust, President and Chief Executive Officer · 2026-08-11 This is important as the company scales its commercial model.The Big Picture: A Unique Position in Stroke Care
Looking across Know Trend's global context, Mobia's themes are distinctly company-unique. No other recent reporters are discussing stroke recovery or paired VNS therapy. The company sits at the intersection of neurostimulation and digital health, but the nearest global keywords (e.g., "data center", "AI") are unrelated. This means the company is riding its own wave, not a broader sector trend, which makes its execution story even more critical. The transcript also reveals a deliberate focus on building awareness and education. The patient story of Tess—a survivor who regained the ability to pick up her son—serves as a powerful emotional anchor. This is a company that understands the importance of both clinical evidence and patient advocacy.That captures the optimism. In summary, Mobia Medical is off to a strong start as a public company. The revenue growth is real, and the reimbursement tailwinds are tangible. The main risk is whether the company can maintain its measured territory expansion while competitors or alternative therapies emerge. For now, the stroke recovery market is ripe for disruption, and Mobia is leading the charge.I just want to remind everyone, this is a market that remains significantly underserved. We believe the opportunity ahead of us is substantial. The patients we serve are getting better.